Caring for children and teens with a chronic illness requires patience and an acceptance that certain life-style changes will have to be made. Additionally, you also have the responsibility of making ...

This year, the Lupus Foundation of America (LFA) is pleased to announce two recipients of grants supporting pediatric lupus research. This year’s recipients are Nayimisha Balmuri, MD, Assistant ...

Systemic lupus erythematosus (SLE) is a multifactorial autoimmune rheumatic disease. Although its highest prevalence is among women of childbearing age, the disease is not confined within this ...

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE: GSK) today ...

Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are ...

Detailed price information for Aurinia Pharm Ord (AUPH-Q) from The Globe and Mail including charting and trades.

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, making it the second biologic available for patients with the disease.The ...

Lupus is associated with chronic morbidity and an increased risk of mortality, and has an unpredictable course. These features emphasize the need for long-term monitoring. Although broadly similar, ...

Andrea Knight, MD, MSCE, Clinician Investigator, Division of Rheumatology, Hospital for Sick Children, and Lupus Foundation of America Medical-Scientific Advisory Council member shared, "Obtaining ...

Belimumab autoinjector is now approved and available for pediatric patients with lupus nephritis. The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for ...